Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Chinese Companies Line Up to Take Advantage of Huawei’s U.S. Troubles
Trending in China: Social Media Applauds Jack Ma’s Detailed Critique of China’s Financial Sector
Trending in China: Female Student Fights ‘Period-Shaming’ – Social Media Discusses the Pros and Cons
Chinese Auto Tech Startup Closes $194 Million Series A Funding Round Led by Baidu
iQiyi to Create Genre-Specific Content to Meet Different Audience Demands
Gaw Capital Inks JV With Manbang Group to Develop Smart Logistics Properties in China
Tesla Recalls Nearly 50,000 U.S.-Made Cars in China over Suspension Problems
Fintech Giant Lufax’s U.S. IPO Could Raise $2.36 Billion
WeChat Judge Won’t Pause Temporary Order Blocking Trump Ban
Mongolia Delivers First Batch of Donated Sheep to China
Signs of Stormy Weather Ahead for One of China’s Largest Semiconductor Makers
Trending in China: Finding Pleasure in the Pain of Everyday Life – China’s Youth Mock Their Own Reality
‘Double 11’ Shopping Fest Faces Covid-19 Supply Chain Pressures
Trending in China: Scalpers Take Advantage of Lack of New iPhone 12s in Stock in China Expands Robot Delivery Service to New City
China Meets 5G Base Station Target 3 Months Early
China Unicom Revenue Growth Remains Flat as Subscribers Fall
Trending in China: Is Education To Blame For China’s Falling Fertility Rate?
Trending in China: Winning Fewer Games and More Battles? PLA Ends Sporting Tradition
China Calls Time on Chipmakers With No Experience, No Technology and No Talent
Biopharma Firm SinoMab BioScience Files $223 million IPO in Hong Kong

By Liu Yanfei and Denise Jia / Oct 31, 2019 04:23 AM / Finance

Photo: VCG

Photo: VCG

Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd. plans to raise as much as HK$1.75 billion ($223 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.

Chinese pharmaceutical company Yunnan Baiyao Group Co. as a cornerstone investor pledged to subscribe for $50 million of shares in the IPO.

SinoMab plans to offer a total of 182 million shares globally, 10% of them in Hong Kong and the rest elsewhere. The offering price will range between HK$7.60 and HK$9.60 a share, according to the prospectus.

The company will start an international roadshow Wednesday; the public offering will begin Thursday; and the shares are scheduled to list Nov. 12.

SinoMab develops therapies for immunological diseases, primarily monoclonal antibody-based biologics, or those that use the body's immune system to attack disease-causing cells.

The company’s flagship product, called SM03, is intended to treat rheumatoid arthritis and is being evaluated in a late-stage study. The company expects to complete the clinical trial and submit a new drug application by mid 2020, the company’s founder and Chief Executive Liang Ruian said Wednesday at a press conference.

The startup doesn’t have any commercialized products or operating revenue. It recorded a net loss of 83.61 million yuan in 2018.

China International Capital Corp. and Orient Securities serve as joint sponsors of the IPO.

Contact reporter Denise Jia (

Share this article
Open WeChat and scan the QR code